Despite advances in guideline-directed medical therapy (GDMT), many patients with heart failure with reduced ejection fraction remain symptomatic, struggle to tolerate or maintain therapy, and experience limited improvement in quality of life. This new therapy overview and operational checklist explores how baroreflex activation therapy, or Barostim, can help address this unmet need. The guide outlines how this novel therapy complements GDMT to improve heart failure symptoms and offers practical, step-by-step considerations for integrating Barostim into clinical practice.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
